Literature DB >> 22744405

Osteoporosis and fracture risk in people with schizophrenia.

Taishiro Kishimoto1, Marc De Hert, Harold E Carlson, Peter Manu, Christoph U Correll.   

Abstract

PURPOSE OF REVIEW: Excessive bone mineral density (BMD) loss has been associated with schizophrenia, but its mechanisms and clinical implications are less clear. The aim of this review was to summarize the risk of osteoporosis and bone fractures in schizophrenia patients. Moreover, we aimed to examine the impact of antipsychotic-induced hyperprolactinemia on bone metabolism. RECENT
FINDINGS: Fifteen of 16 studies (93.8%) reported lower BMD or higher prevalence of osteoporosis in at least one region, or in at least one subgroup of schizophrenia patients compared with controls, but results were inconsistent across measured areas. Higher fracture risk was associated with schizophrenia in 2/2 studies (independently: n = 1), and 3/4 studies with antipsychotics. Reasons for this difference include insufficient exercise, poor nutrition, smoking, alcohol use, and low vitamin D levels. Altogether, 9/15 (60.0%) studies examining the relationship between antipsychotic-induced hyperprolactinemia and BMD loss found some effects of hyperprolactinemia. However, results were mixed, samples and effects were small, and only two studies were prospective.
SUMMARY: Schizophrenia is associated with reduced BMD and fracture risk. Prevention, early detection, and intervention are required. The relative contributions of antipsychotic-related hyperprolactinemia and unhealthy lifestyle behaviors remain unclear, needing to be assessed in well designed, prospective studies, including bone turnover markers as intermediary endpoints.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22744405      PMCID: PMC3566242          DOI: 10.1097/YCO.0b013e328355e1ac

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  75 in total

1.  The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.

Authors:  O Chaki; I Yoshikata; R Kikuchi; M Nakayama; Y Uchiyama; F Hirahara; I Gorai
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

2.  Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study.

Authors:  George Abraham; Wynn Wynn Paing; Joanne Kaminski; Ashok Joseph; Eva Kohegyi; Richard C Josiassen
Journal:  Am J Psychiatry       Date:  2003-09       Impact factor: 18.112

Review 3.  Quantitative ultrasond in the assessment of osteoporosis.

Authors:  Giuseppe Guglielmi; Francesca de Terlizzi
Journal:  Eur J Radiol       Date:  2009-08-03       Impact factor: 3.528

4.  Mortality after all major types of osteoporotic fracture in men and women: an observational study.

Authors:  J R Center; T V Nguyen; D Schneider; P N Sambrook; J A Eisman
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

5.  Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain.

Authors:  Katherine J Motyl; Ingrid Dick-de-Paula; Ann E Maloney; Sutada Lotinun; Sheila Bornstein; Francisco J A de Paula; Roland Baron; Karen L Houseknecht; Clifford J Rosen
Journal:  Bone       Date:  2011-08-11       Impact factor: 4.398

6.  Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics.

Authors:  Hong Liu-Seifert; Bruce J Kinon; Jonna Ahl; Shaw Lamberson
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

7.  Osteoporosis in patients with schizophrenia.

Authors:  Martina Hummer; Peter Malik; Rudolf W Gasser; Alex Hofer; Georg Kemmler; Roy Cesar Moncayo Naveda; Maria A Rettenbacher; W Wolfgang Fleischhacker
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

8.  Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

Authors:  Veronica O'Keane; Anna Maria Meaney
Journal:  J Clin Psychopharmacol       Date:  2005-02       Impact factor: 3.153

Review 9.  Physical illness and schizophrenia: a review of the literature.

Authors:  S Leucht; T Burkard; J Henderson; M Maj; N Sartorius
Journal:  Acta Psychiatr Scand       Date:  2007-11       Impact factor: 6.392

10.  Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment.

Authors:  Oliver D Howes; Michael J Wheeler; Anna-Maria Meaney; Veronica O'Keane; Ignac Fogelman; Glen Blake; Robin M Murray; Shubulade Smith
Journal:  J Clin Psychopharmacol       Date:  2005-06       Impact factor: 3.153

View more
  30 in total

1.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

Review 2.  Bone, brain & beyond.

Authors:  Alexandre Chamouni; Christiane Schreiweis; Franck Oury
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

3.  Increased risk of fracture in patients with bipolar disorder: a nationwide cohort study.

Authors:  Chih-Chao Hsu; Yi-Chao Hsu; Kuang-Hsi Chang; Chang-Yin Lee; Lee-Won Chong; Yu-Chiao Wang; Chung-Y Hsu; Chia-Hung Kao
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-05-30       Impact factor: 4.328

4.  Omega-3 fatty acids supplementation with lithium and aripiprazole for improving the balance of circulating hormones and brain neurotransmitters in manic mice model.

Authors:  Pandiyan Arunagiri; Elumalai Balamurugan; Murugesan Saravanakumar; Mackraj Irene
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-12-30       Impact factor: 3.000

5.  Outcomes of Physiotherapy on Activities of Daily Living and Discharge to the Community in Psychiatric Long-term Care Ward Patients.

Authors:  Munetsugu Kota; Sae Uezono; Yusuke Ishibashi; Shouichi Kuramochi; Sousuke Kitakaze; Seiji Kaganoi
Journal:  Phys Ther Res       Date:  2022-05-13

6.  Do psychiatric comorbidities influence inpatient death, adverse events, and discharge after lower extremity fractures?

Authors:  Mariano E Menendez; Valentin Neuhaus; Arjan G J Bot; Mark S Vrahas; David Ring
Journal:  Clin Orthop Relat Res       Date:  2013-06-30       Impact factor: 4.176

7.  Factors Affecting the Management of Somatic Comorbidity in Tunisian Patients with Schizophrenia.

Authors:  Jihene Ben Thabet; Nada Charfi; Wafa Dalhoum; Sourour Yaich; Manel Maâlej Bouali; Sana Omri; Nasreddine Zouari; Lobna Zouari; Jamel Damak; Mohamed Maâlej
Journal:  Psychiatr Q       Date:  2019-03

8.  Osteoporosis associated with antipsychotic treatment in schizophrenia.

Authors:  Haishan Wu; Lu Deng; Lipin Zhao; Jingping Zhao; Lehua Li; Jindong Chen
Journal:  Int J Endocrinol       Date:  2013-04-17       Impact factor: 3.257

9.  Bone Mineral Density as a Marker of Cumulative Estrogen Exposure in Psychotic Disorder: A 3 Year Follow-Up Study.

Authors:  Christine van der Leeuw; Sanne Peeters; Patrick Domen; Marinus van Kroonenburgh; Jim van Os; Machteld Marcelis
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

10.  Chlorpromazine-Induced Hyperprolactinemia on Rat's Uterus.

Authors:  Zahra Zamani; Samad Zare; Rajabali Sadrkhanlou; Abbas Ahmadi; Elham Movahed
Journal:  Iran Biomed J       Date:  2015-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.